Health care companies in the US have had to shell out to fund Obamacare, while mega-cap pharmaceutical companies have been navigating patent cliffs in recent years. AXA Framlington's health care manager Gemma Game explains some of the reasons why investors should stay positive on the sector.
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
